Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05417867
Other study ID # 20-009279
Secondary ID NCI-2022-01231
Status Recruiting
Phase
First received
Last updated
Start date April 14, 2021
Est. completion date October 15, 2024

Study information

Verified date October 2023
Source Mayo Clinic
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This pilot study seeks to understand how changes in the bacteria composition (microbiome) of the gut may be associated with the occurrence of chemotherapy-induced nausea (CIN) in women undergoing chemotherapy for stage I-III breast cancer. Patients undergoing chemotherapy may experience nausea as a result of their treatment. Known risk factors for CIN do not explain the differences in CIN occurrence between patients, but changes in the functions of the gut microbiome may be related to the occurrence of CIN. This study collects stool samples from breast cancer patients before and after chemotherapy to evaluate how changes in the microbiome may be associated with CIN.


Description:

PRIMARY OBJECTIVES: I. Evaluate the feasibility of patient recruitment and retention, as well as specimen collection. II. Estimate the effect size for changes in gut microbiome composition profiles and metabolites in stool as well as blood from T1 to T2 that are associated with the occurrence of CIN. III. Evaluate associations between patient reported demographic and clinical characteristics, comorbidities at T1, and changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 with the occurrence of CIN. OUTLINE: Patients undergo collection of stool and blood samples and complete questionnaires at baseline and 3-5 days following initiation of standard of care chemotherapy.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date October 15, 2024
Est. primary completion date April 26, 2024
Accepts healthy volunteers No
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Subjects with a diagnosis of early stage breast cancer, planning to receive moderate to highly emetogenic chemotherapy will be recruited at Mayo Clinic, Arizona and Mayo Clinic Florida - At least 20 years of age - Last chemotherapy more than 3 years ago - Scheduled to receive moderate to highly emetogenic chemotherapy with or without targeted therapies including immunotherapies Exclusion Criteria: - Metastatic disease - Concurrent radiation therapy - Concurrent antibiotic treatment

Study Design


Intervention

Procedure:
Biospecimen Collection
Undergo collection of stool and blood samples
Other:
Questionnaire Administration
Complete questionnaires

Locations

Country Name City State
United States Mayo Clinic in Florida Jacksonville Florida
United States Mayo Clinic in Rochester Rochester Minnesota
United States Mayo Clinic in Arizona Scottsdale Arizona

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patients approached Assessed using descriptive statistics. Up to 24 months
Primary Number of patients enrolled Assessed using descriptive statistics. Up to 24 months
Primary Number of patients who completed the questionnaires at both assessments Assessed using descriptive statistics. At baseline and 3-5 days after initiation of chemotherapy
Primary Number of patients who provided stool samples at both assessments Assessed using descriptive statistics. At baseline and 3-5 days after initiation of chemotherapy
Primary Bacterial composition of stool samples All stool samples will be processed for deoxyribonucleic acid extraction. The hypervariable regions V3 and V4 of the bacterial 16S ribosomal ribonucleic acid (rRNA) gene will be sequenced to determine bacterial composition. After quality control, 16S rRNA reads will be analyzed to determine operational taxonomic units (OTU) for T1 and T2 samples using QIIME software. Alpha (within sample) diversity and beta (between sample) diversity will be analyzed using nonmetric multidimensional scaling ordination and the effect size for changes in OTUs in gut microbiome composition profiles from T1 to T2 in patients who do and do not report chemotherapy-induced nausea (CIN) at T2 as measured by questionnaire, will be determined using linear discriminant analysis effect size. Up to study completion
Primary Differences in demographic between patients who do and do not report CIN Evaluated using parametric and non-parametric tests. The changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 associated with the occurrence of CIN will be evaluated using Kruskal-Wallis tests. Up to study completion
Primary Differences in clinical characteristics between patients who do and do not report CIN Evaluated using parametric and non-parametric tests. The changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 associated with the occurrence of CIN will be evaluated using Kruskal-Wallis tests. Up to study completion
Primary Differences in comorbidities between patients who do and do not report CIN Evaluated using parametric and non-parametric tests. The changes in gastrointestinal and neuropsychological symptoms, food intake as well as exercise from T1 to T2 associated with the occurrence of CIN will be evaluated using Kruskal-Wallis tests. Up to study completion
See also
  Status Clinical Trial Phase
Recruiting NCT05368428 - Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer N/A
Active, not recruiting NCT02212860 - Stereotactic Image-Guided Neoadjuvant Ablative Radiation Then Lumpectomy N/A
Terminated NCT02876640 - Retinoid 9cUAB30 in Producing a Biologic Effect in Patients With Early Stage Breast Cancer Phase 1
Recruiting NCT05945290 - Pre-analytical Factors Affecting ctDNA Analysis in Early and Locally Advanced Breast Cancer
Recruiting NCT06387173 - Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer
Active, not recruiting NCT02167490 - Sentinel Node Vs Observation After Axillary Ultra-souND N/A
Recruiting NCT02889874 - EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer N/A
Active, not recruiting NCT02095743 - Tolerance of PICC Line Versus Implanted Port for Adjuvant Chemotherapy in Early Breast Cancer Phase 2
Completed NCT03003611 - Observational Trial on the Impact of Hypnose Used as a Sedation in Oncology Surgery in Breast Cancer N/A
Recruiting NCT06113016 - Prevention of Frailty With Fisetin and Exercise (PROFFi) in Breast Cancer Survivors Phase 2

External Links